Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Уроки первичной профилактики на примере использования розувастатина
Уроки первичной профилактики на примере использования розувастатина
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
На примере обзора исследования JUPITER обсуждается возможность применения статинов у практически здоровых людей с некоторыми факторами риска. Приведены положительные результаты применения розувастатина у лиц с пониженным или нормальным уровнем холестерина липопротеидов низкой плотности. Поскольку наблюдаемые больные имели лишь один фактор риска – высокий уровень С-реактивного белка, обсуждается роль воспаления в атерогенезе и значение многочисленных плейотропных эффектов статинов, в частности розувастатина. Показана зависимость плейотропных эффектов статинов от дозы и длительности приема.
Ключевые слова: статины, розувастатин, первичная профилактика, плейотропные эффекты.
Key words: statins, rosuvastatin, primary prevention, pleiotropic effects.
Ключевые слова: статины, розувастатин, первичная профилактика, плейотропные эффекты.
________________________________________________
Key words: statins, rosuvastatin, primary prevention, pleiotropic effects.
Полный текст
Список литературы
1. 1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
2. Athyros VG, Papageorgiou AA, Mercouris BR et al Treatment with atorvastatin to the National Cholesterol Educational Program goal versus «usual» care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18 (4): 220–8.
3. MacMahon S, Sharpe N, Gamble G, Hart H et al. on behalf of the LIPID Trial Research Group. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis. Results of the LIPID Atherosclerosis substudy. Circulation 1998; 97: 1784–90.
4. MRC/BHF Heart Protection Study of cholesterol lowering with Simvastatin in 20 536 high-risk individuals: a randomized placebo controlled trial. The Lancet 2002; 360: 7–22.
5. Ridker PM, Rifai N, Pfeffer MA et al. Cholesterol and Recurrent Events (CARE) investigators: inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839–44.
6. Shepherd J, Cobbe SM, Ford I, Isles CG et al for the West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995; 333 (20): 1301–7.
7. Downs GR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of Air Force Texas coronary Atherosclerosis Study. JAMA 1998; 279: 1615–22.
8. Sever PS, Dahlof B, Poulter NR et al for the ASCOT Investigations. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149–58.
9. Ridker PM, Danielson E, Fonseca FA et al Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21): 2195–207.
10. Аронов Д.М. Каскад терапевтических эффектов статинов. Кардиология. 2004; 10: 85–94.
11. Аронов Д.М. Лечение и профилактика атеросклероза. М.: Триада-Х, 2000.
12. Boven van A, Jukema JW, Zwinderman AN et al. on behalf of the REGRESS Study Group Reduction of transient myocardial ischemia with pravastatin in addition of the Conventional treatment in patients with angina pectoris. Circulation 1996; 94: 1503–5.
13. Wassmann S, Faul A, Hennen B et al. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003; 31: 98–103.
14. Nakashima Y, Toyokawa T, Tanaka S et al. «Simvastatin increases plasma NO2- and NO3-levels in patients with hypercholesterolemia». Atherosclerosis 1996; 127: 43–7.
15. Strey CH, Voung JM et al. Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart 2006; 92 (11): 1603–9.
16. John S, Delles C, Jacobi J, Schlaich MP. Rapid improvement of nitric oxide biovailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001; 37 (5): 1351–8135.
17. Taneva E, Borucki K, Wiens L. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol 2006; 97 (7): 1002–6.
18. Арутюнов Г.П., Карцева Т.П., Воеводина Н.Ю. и др. Влияние агрессивной терапии симвастатином у больных с острым коронарным синдромом и исходно нормальным уровнем ХС ЛПНП на сердечно-сосудистые исходы (ЛАОКООН), пилотное рандомизированное исследование. Тер. арх. 2005; 9: 53–60.
19. Link A, Ayadhi T et al. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006; 27: 2945–55.
20. Fichtischerer S, Schmidt-Lucke C et al. Differential effects of shot-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD clinical evidence for «pleotropic» functions of statin therapy. Eur Heart J 2006; 27 (10): 1182–90.
21. Eto M, Rathgeb L, Cosentino F et al Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells. J Cardiovasc Pharmacol 2006; 45 (5): 663–7.
22. Morrow DA, de Lemos JA et al Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006; 114 ( 4): 281–8.
23. Muhlestein JB, Anderson JL, Horne BD et al Intermountain Heart Collaborative Study Group. Early effects of statins in patients with coronary artery disease and high C-reactive protein. Am J Cardiol 2004; 94 (9): 1107–12.
24. Ushiroyama T, Nosaka S, Ueki M. Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic hypertriglyceridemic women. Int J Cardiol 2006; 113 (1): 66–75.
25. Galle J, Hansen-Hagge T et al. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 2006; 7: 219–26.
26. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993; 1165 (3): 335–8.
27. Sumi D, Hayashi T, Thakur NK et al. A HMG-CoA reductase inhibitor possesses a potent antiatherosclerosis effect other than serum lipid lowering effects – the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 2001; 155 (2): 347–57.
28. Rikitake Y, Kawashima S et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterolfed rabbits. Atherosclerosis 2001; 154 (1): 87–96.
29. Cay S, Cagirci G, Sen N et al. Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin. Cardiovasc Drugs Ther 2010; 24 (1): 41–7.
30. Gomez-Garcia A, Martinez Torres G, Ortega-Pierres LE et al Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia. Rev Esp Cardiol 2007; 60 (12): 1242–9.
31. Erbs S, Beck EB, Linke A et al. High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling-results from a randomized, double-blind, and placebo-controlled study. Int J Cardiol 2011; 146 (1): 56–63. Epub 2010 Mar 16.
32. Parson HK, Bundy MA, Dublin CB et al. Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes. Diabetes Metab Syndr Obes 2010; 3: 19–26.
33. Tapia-Perez JH, Sanchez-Aguilar M, Torres-Corzo JG et al. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J Neurotrauma 2008; 25 (8): 1011–7.
34. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295 (13): 1556–65. Epub 2006 Mar 13.
2. Athyros VG, Papageorgiou AA, Mercouris BR et al Treatment with atorvastatin to the National Cholesterol Educational Program goal versus «usual» care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18 (4): 220–8.
3. MacMahon S, Sharpe N, Gamble G, Hart H et al. on behalf of the LIPID Trial Research Group. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis. Results of the LIPID Atherosclerosis substudy. Circulation 1998; 97: 1784–90.
4. MRC/BHF Heart Protection Study of cholesterol lowering with Simvastatin in 20 536 high-risk individuals: a randomized placebo controlled trial. The Lancet 2002; 360: 7–22.
5. Ridker PM, Rifai N, Pfeffer MA et al. Cholesterol and Recurrent Events (CARE) investigators: inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839–44.
6. Shepherd J, Cobbe SM, Ford I, Isles CG et al for the West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995; 333 (20): 1301–7.
7. Downs GR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of Air Force Texas coronary Atherosclerosis Study. JAMA 1998; 279: 1615–22.
8. Sever PS, Dahlof B, Poulter NR et al for the ASCOT Investigations. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149–58.
9. Ridker PM, Danielson E, Fonseca FA et al Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21): 2195–207.
10. Аронов Д.М. Каскад терапевтических эффектов статинов. Кардиология. 2004; 10: 85–94.
11. Аронов Д.М. Лечение и профилактика атеросклероза. М.: Триада-Х, 2000.
12. Boven van A, Jukema JW, Zwinderman AN et al. on behalf of the REGRESS Study Group Reduction of transient myocardial ischemia with pravastatin in addition of the Conventional treatment in patients with angina pectoris. Circulation 1996; 94: 1503–5.
13. Wassmann S, Faul A, Hennen B et al. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003; 31: 98–103.
14. Nakashima Y, Toyokawa T, Tanaka S et al. «Simvastatin increases plasma NO2- and NO3-levels in patients with hypercholesterolemia». Atherosclerosis 1996; 127: 43–7.
15. Strey CH, Voung JM et al. Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart 2006; 92 (11): 1603–9.
16. John S, Delles C, Jacobi J, Schlaich MP. Rapid improvement of nitric oxide biovailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001; 37 (5): 1351–8135.
17. Taneva E, Borucki K, Wiens L. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol 2006; 97 (7): 1002–6.
18. Арутюнов Г.П., Карцева Т.П., Воеводина Н.Ю. и др. Влияние агрессивной терапии симвастатином у больных с острым коронарным синдромом и исходно нормальным уровнем ХС ЛПНП на сердечно-сосудистые исходы (ЛАОКООН), пилотное рандомизированное исследование. Тер. арх. 2005; 9: 53–60.
19. Link A, Ayadhi T et al. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006; 27: 2945–55.
20. Fichtischerer S, Schmidt-Lucke C et al. Differential effects of shot-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD clinical evidence for «pleotropic» functions of statin therapy. Eur Heart J 2006; 27 (10): 1182–90.
21. Eto M, Rathgeb L, Cosentino F et al Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells. J Cardiovasc Pharmacol 2006; 45 (5): 663–7.
22. Morrow DA, de Lemos JA et al Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006; 114 ( 4): 281–8.
23. Muhlestein JB, Anderson JL, Horne BD et al Intermountain Heart Collaborative Study Group. Early effects of statins in patients with coronary artery disease and high C-reactive protein. Am J Cardiol 2004; 94 (9): 1107–12.
24. Ushiroyama T, Nosaka S, Ueki M. Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic hypertriglyceridemic women. Int J Cardiol 2006; 113 (1): 66–75.
25. Galle J, Hansen-Hagge T et al. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 2006; 7: 219–26.
26. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993; 1165 (3): 335–8.
27. Sumi D, Hayashi T, Thakur NK et al. A HMG-CoA reductase inhibitor possesses a potent antiatherosclerosis effect other than serum lipid lowering effects – the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 2001; 155 (2): 347–57.
28. Rikitake Y, Kawashima S et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterolfed rabbits. Atherosclerosis 2001; 154 (1): 87–96.
29. Cay S, Cagirci G, Sen N et al. Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin. Cardiovasc Drugs Ther 2010; 24 (1): 41–7.
30. Gomez-Garcia A, Martinez Torres G, Ortega-Pierres LE et al Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia. Rev Esp Cardiol 2007; 60 (12): 1242–9.
31. Erbs S, Beck EB, Linke A et al. High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling-results from a randomized, double-blind, and placebo-controlled study. Int J Cardiol 2011; 146 (1): 56–63. Epub 2010 Mar 16.
32. Parson HK, Bundy MA, Dublin CB et al. Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes. Diabetes Metab Syndr Obes 2010; 3: 19–26.
33. Tapia-Perez JH, Sanchez-Aguilar M, Torres-Corzo JG et al. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J Neurotrauma 2008; 25 (8): 1011–7.
34. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295 (13): 1556–65. Epub 2006 Mar 13.
Авторы
Д.М.Аронов
ФГУ Государственный научно-исследовательский центр профилактической медицины Минздравсоцразвития РФ, Москва
State Research Center of Preventive Medicine, Ministry of Health and Social Development of the Russian Federation
ФГУ Государственный научно-исследовательский центр профилактической медицины Минздравсоцразвития РФ, Москва
________________________________________________
State Research Center of Preventive Medicine, Ministry of Health and Social Development of the Russian Federation
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.